Chenodeoxycholic acid reduces feed intake and modulates the expression and hepatic lipogenic genes in broiler chickens

News

Yourlocation： Home > News > Chenodeoxycholic acid reduces feed intake and modulates the expression and hepatic lipogenic genes in broiler chickens

Chenodeoxycholic acid inhibits feed intake and reduces body weight in broiler chickens: Chickens fed CDCA-supplemented diets over a period about 15 days showed a significant and a dose-dependent decrease in feed intakecompared to control birds (9–12% and 13–32% for CDCA 0.1 and 0.5%, respectively, ). CDCA-mediated feed intake inhibition started at d2 post-treatment, however, the difference was statistically discernable only from d7 to d15. Concomitant with these changes, CDCA-fed chickens exhibited a significant dosedependent lower body weight (from d3 to d15 post-treatment) compared to the control group (3–6% and 7–11% for CDCA 0.1 and 0.5%, respectively).
Chenodeoxycholic acid alters plasma glucose levels in broiler chickens: Chickens fed CDCA-supplemented diets manifested a significant decrease in plasma glucose (287.6 ± 4 vs. 264.8 ± 3 and 263.1 ± 3 mg/dL at d10 and 292.0 ± 3 vs. 280.3 ± 3 and 278.1 ± 2 mg/dL at d15 post-treatment in control, CDCA 0.1% and CDCA 0.5%, respectively). CDCA treatment did not affect the circulating levels of triglycerides, NEFA, uric acid, and T3. Diet-containing CDCA inhibits cumulative feed intake and reduced body weight in broiler chickens. 4 week-old broilers were fed diets supplemented with CDCA at 0, 0.2 or 0.5% for two weeks, respectively.
Chenodeoxycholic acid (CDCA) alters the expression of feeding-related hypothalamic neuropeptides in broiler chickens: Compared to the control group, hypothalami from 0.5% CDCAtreated chickens showed significantly higher mRNA levels of NPY(1 ± 0.01 vs. 2.37 ± 0.4, P < 0.05), AgRP (1 ± 0.3 vs. 6.29 ± 1, P < 0.05, Fig. 3b), ORX (1 ± 0.1 vs. 7 ± 1.3, P < 0.05, Fig. 3c), CRH(1 ± 0.2 vs. 9.36 ± 3, P < 0.05), Ghrl (1 ± 0.06 vs. 18.4 ± 5,P < 0.05), and MC1R (1 ± 0.03 vs. 3.19 ± 0.8, P < 0.05,). CDCA treatment induced ORXR1 expression and decreased SOCS3 mRNA abundance in a dose-dependent manner compared to the control group (1 ± 0.1 vs. 3.41 ± 1.4 and 9 ± 4 for ORXR1 and 1 ± 0.01 vs. 0.83 ± 0.06 and 0.6 ± 0.1 for SOCS3 in the control, CDCA 0.1% and CDCA 0.5%, respectively, P < 0.05). Even thought, it did not affect the hypothalamic expression of MC4R, MC5R, and CRP.